Methods and compositions for treating pain

12246,058

17/153165

January 20, 2021

The disclosure provides polypeptides and pharmaceutical compositions thereof. Such polypeptides can be useful, for example, in treating pain in a subject. In some embodiments, the polypeptides are useful for treating neuropathic and/or inflammatory pain.

Creighton University (Omaha, NE, US)

Creighton University (Omaha, NE, US)

1. A method of treating pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a polypeptide having the amino acid sequence shown in to SEQ ID NO: 2, or a pharmaceutical composition thereof.

2. The method of claim 1 , wherein administration of the polypeptide or a pharmaceutical composition thereof increases glutamate delta 1 receptor (GluD1)-cerebellin 1 (Cbln1) signaling.

3. A method of increasing GluD1-Cbln1 signaling in a subject in need thereof, the method comprising administering to the subject a polypeptide having the amino acid sequence shown in SEQ ID NO:2, or a pharmaceutical composition thereof.

4. The method of claim 1 , wherein the pain comprises neuropathic pain.

5. The method of claim 4 , wherein the neuropathic pain is associated with nerve compression, nerve damage, abnormal processing of pain signals, or a combination thereof.

6. The method of claim 4 , wherein the neuropathic pain is a side effect of a therapeutic agent.

7. The method of claim 6 , wherein the therapeutic agent is a chemotherapy.

8. The method of claim 7 , wherein the chemotherapy comprises a taxane, a platinum-based agent, a vinca alkaloid, an epothilone, eribulin, bortezomib, thalidomide, or a combination thereof.

9. The method of claim 1 , wherein the subject has chemotherapy-induced neuropathic pain.

10. The method of claim 1 , wherein the pain comprises inflammatory pain.

11. The method of claim 10 , wherein the inflammatory pain is associated with surgery, trauma, arthritis, or a combination thereof.

12. The method of claim 1 , wherein the polypeptide or a pharmaceutical composition thereof is administered to the central nervous system of the subject.

13. A method of reducing an amount of opioid administered to a subject, the method comprising administering to the subject a therapeutically effective amount of a polypeptide having the amino acid sequence shown in SEQ ID NO: 2, or a pharmaceutical composition thereof.

5122458 June 1992 Post et al.
5168062 December 1992 Stinski
7213538 May 2007 Han et al.
2006/0040354 February 2006 O'Keefe
WO 1998/010088 March 1998
WO 2005/073384 August 2005

Zhong, W., Barde, S., Mitsios, N., Adori, C., Oksvold, P., von Feilitzen, K., O'Leary, L., Csiba, L., Hortobagy, T., Szocsics, P., Mechawar, N., Magloczky, Z., Renner, E., Palkovits, M., Uhlen, M., Mulder, J., Hokfet, T. The neuropeptide landscape of human prefrontal cortex. PNAS. 2022. 119(33) 1-12. (Year: 2022). cited by examiner
Burbach, J.P.H., Neuropeptides from concept to online database www.neuropeptides.nl. 2010. European Journal of Pharmacology. 626:27-48. (Year: 2010). cited by examiner
Sabnis, S., Narasimhan, K., Chettiar P., Gakare, S., Shelkar, G., Asati, D., Thakur, Dravid, S., Intravenous recombinant cerebellin 1 treatment restores spinal glutamate delta 1 receptor signalingand mitigates chronic pain. British Journal of Pharmacology. Dec. 3, 2023. doi: 10.1111/bph.16296, (Year: 2023). cited by examiner
Sandor, K., Krishnan, S., Mohan Agalave, N., Krock, E., Villarreal Salcido, J., Fernandez-Zafra, T., Khoonsari, P., Svensson, C., Kultima, K. Spinal injection of newly identified cerebellin-1 and cerebellin-2 peptides induce mechanical hypersensitivity in mice. Neuropeptides. 2018. 53-59. (Year: 2018). cited by examiner
Krishnan et al. Autism gene Ube3a and seizures impair sociability by repressing VTA Cbln1. Nature. 2017. 543:507-512. (Year: 2017). cited by examiner
Cherny et al. Opioid Pharmacotherapy in the Management of Cancer Pain. A Survey of Strategies Used by Pain Physicians for the Selection of Analgesic Drugs and Routes of Administration. 1995. Cancer. 76(7):1283-1293. (Year: 1995). cited by examiner
Glare et al. Pain in Cancer Survivors. 2014. J Clin Oncol 32(16): 1739-1747. (Year: 2014). cited by examiner
Elegheert, Kakegawa, Clay, Shanks, Behiels, Matsuda, Kohda, Miura, Rossmann, Mitakidis, Motohashi, Chang, Siebold, Greger, Nakagawa, Yuzaki, Aricescu, A., Structural basis for integration of GluD receptors within synaptic organizer complexes. Science. 2016. 353(6296) 295-299. (Year: 2016). cited by examiner
Elegheert, et al., Supplementary Information. A., Structural basis for integration of GluD receptors within synaptic organizer complexes. Science. 2016. 353(6296) 1-67. (Year: 2020). cited by examiner
Gandhi, P., 2020. Organisation of Glutamatergic Inputs to Central Amygdala. ProQuest No. 28021786. Doctoral Dissertation, Creighton University. (Year: 2020). cited by examiner
Quintao, N., Santin, J., Stoeberl, L., Correa, T., Melato, J., Costa, R., Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: PPARγ Agonists as a Promising Tool. Frontiers. 2019. 13: 1-17. (Year: 2019). cited by examiner
Sandor et al. Spinal injection of newly identified cerebellin-1 and cerebellin-2 peptides induce mechanical hypersensitivity in mice. Neuropeptides. 2018; 69:53-59. (Year: 2018). cited by examiner
Allen et al., “Left and right hemispheric lateralization of the amygdala in pain,” Prog Neurobiol, 2021,196: 14 pages. cited by applicant
Arbuthnot et al., “In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector,” Human gene therapy, Aug. 20, 1996, 7(13):1503-1514. cited by applicant
Asokan et al., “The AAV vector toolkit: poised at the clinical crossroads,” Molecular Therapy, Apr. 1, 2012, 20(4):699-708. cited by applicant
Batt et al., “Characterization of the polyomavirus late polyadenylation signal,” Molecular and cellular biology, Sep. 1, 1995, 15(9):4783-4790. cited by applicant
Bird et al., “Protein kinase A-dependent enhanced NMDA receptor function in pain-related synaptic plasticity in rat amygdala neurones,” The Journal of physiology, May 2005, 564(3):907-921. cited by applicant
Boshart et al., “A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus,” Cell, Jun. 1, 1985, 41(2):521-530. cited by applicant
Boulikas et al. “Nature of DNA sequences at the attachment regions of genes to the nuclear matrix.,” Journal of cellular biochemistry, May 1993, 52(1):14-22. cited by applicant
Braz et al., “Parallel “pain” pathways arise from subpopulations of primary afferent nociceptor.,” Neuron, Sep. 15, 2005, 47(6):787-793. cited by applicant
Carrasquillo et al., “Activation of the extracellular signal-regulated kinase in the amygdala modulates pain perception,” Journal of Neuroscience, Feb. 14, 2007, 27(7):1543-1551. cited by applicant
Chen et al., “Expression of rat bone sialoprotein promoter in transgenic mice,” Journal of bone and mineral research, May 1996, 11(5):654-664. cited by applicant
Cheng et al., “Role of extracellular signal-regulated kinase in synaptic transmission and plasticity of a nociceptive input on capsular central amygdaloid neurons in normal and acid-induced muscle pain mice,” Journal of Neuroscience, Feb. 9, 2011, 31(6):2258-2270. cited by applicant
Colloca et al., “Neuropathic pain,” Nat Rev Dis Primers, Feb. 16, 2017, 3:17002, 19 pages. cited by applicant
De Lacalle et al., “Calcitonin gene-related peptide-like immunoreactivity marks putative visceral sensory pathways in human brain,” Neuroscience, Sep. 7, 2000, 100(1):115-130. cited by applicant
Delgado et al., “Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults,” Journal of the American Academy of Orthopaedic Surgeons, Global research & reviews, Mar. 2018, 2(3): 1-6. cited by applicant
D'Hanis et al., “Topography of thalamic and parabrachial calcitonin gene-related peptide (CGRP) immunoreactive neurons projecting to subnuclei of the amygdala and extended amygdala,” Journal of Comparative Neurology, Nov. 20, 2007, 505(3):268-291. cited by applicant
Dixon et al., “Staircase bioassay: the up-and-down method,” Neuroscience & Biobehavioral Reviews, Mar. 1, 1991, 15(1):47-50. cited by applicant
Dobolyi et al., “Calcitonin gene-related peptide-containing pathways in the rat forebrain,” Journal of Comparative Neurology, Aug. 15, 2005, 489(1):92-119. cited by applicant
Fisher et al., “Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis,” Journal of virology, Jan. 1, 1996, 70(1):520-532. cited by applicant
Gao et al., “Orphan glutamate receptor δ1 subunit required for high-frequency hearing,” Molecular and cellular biology, Jun. 15, 2007, 27(12):4500-4512. cited by applicant
Gauriau et al., “Pain pathways and parabrachial circuits in the rat,” Experimental physiology, Mar. 2002, 87(2):251-258. cited by applicant
Gossen et al., “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters,” Proceedings of the National Academy of Sciences., Jun. 15, 1992, 89(12):5547-5551. cited by applicant
Gossen et al., “Transcriptional activation by tetracyclines in mammalian cells. Science,” Jun. 23, 1995, 268(5218): 5 pages. cited by applicant
Hagedorn et al., “S/MAR element facilitates episomal long-term persistence of adeno-associated virus vector genomes in proliferating cells,” Human gene therapy, Dec. 1, 2017, 28(12): 29 pages. cited by applicant
Han et al., “Elucidating an affective pain circuit that creates a threat memory,” Cell, Jul. 16, 2015, 162(2): 13 pages. cited by applicant
Hansal et al., “Cutting edge: Induction of antigen-specific hyporesponsiveness by transplantation of hemopoietic cells containing an MHC class I transgene regulated by a lymphocyte-specific promoter,” The Journal of Immunology, Aug. 1, 1998, 161(3): 7 pages. cited by applicant
Harvey et al., “Inducible control of gene expression: prospects for gene therapy,” Current opinion in chemical biology, Jan. 1, 1998, 2(4):512-518. cited by applicant
Hepp et al., “Glutamate receptors of the delta family are widely expressed in the adult brain,” Brain Structure and Function, Sep. 2015, 220(5):2797-2815. cited by applicant
Iijima et al., “Activity-dependent repression of Cb1n1 expression: mechanism for developmental and homeostatic regulation of synapses in the cerebellum,” Journal of Neuroscience, Apr. 29, 2009, 29(17):5425-5434. cited by applicant
Iijima et al., “SAM68 regulates neuronal activity-dependent alternative splicing of neurexin-1,” Cell, Dec. 23, 2011, 147(7):1601-1614. cited by applicant
Ikeda et al., “NMDA receptor-independent synaptic plasticity in the central amygdala in the rat model of neuropathic pain,” Pain, Jan. 1, 2007, 127(1-2):161-172. cited by applicant
Ji et al., “5-HT2C receptor knockdown in the amygdala inhibits neuropathic-pain-related plasticity and behaviors,” Journal of Neuroscience, Feb. 8, 2017, 37(6):1378-1393. cited by applicant
Ji et al., “Fear extinction learning ability predicts neuropathic pain behaviors and amygdala activity in male rats,” Molecular pain, Oct. 2018, 14: 1-13. cited by applicant
Kidd et al., “Mechanisms of inflammatory pain,” British journal of anaesthesia, Jul. 1, 2001, 87(1):3-11. cited by applicant
Kim et al., “An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain,” Sep. 1, 1992, 50(3):355-363. cited by applicant
Konno et al., “Enriched expression of GluD1 in higher brain regions and its involvement in parallel fiber-interneuron synapse formation in the cerebellum,” Journal of Neuroscience, May 28, 2014, 34(22):7412-7424. cited by applicant
Kruger et al., “Calcitonin gene-related peptide (CGRP) in the rat central nervous system: patterns of immunoreactivity and receptor binding sites,” Brain research, Nov. 1, 1988, 463(2):223-244. cited by applicant
Lein et al. “Genome-wide atlas of gene expression in the adult mouse brain,” Nature, Jan. 2007, 445(7124):168-176. cited by applicant
Levitt et al., “Definition of an efficient synthetic poly (A) site,” Genes & Development, Jul. 1, 1989, 3(7):1019-1025. cited by applicant
Li et al., “Spared nerve injury differentially alters parabrachial monosynaptic excitatory inputs to molecularly specific neurons in distinct subregions of the central amygdala,” Pain, Jan. 2020, 61(1):166-176. cited by applicant
Liu et al., “Modulation of burst firing of neurons in nucleus reticularis of the thalamus by GluN2C-containing NMDA receptors,” Molecular pharmacology, Aug. 1, 2019, 96(2):193-203. cited by applicant
Liu wet al., “Striatal glutamate delta-1 receptor regulates behavioral flexibility and thalamostriatal connectivity,” Neurobiology of disease, Apr. 1, 2020, 137:104746, 11 pages. cited by applicant
Lykken et al., “Recent progress and considerations for AAV gene therapies targeting the central nervous system,” Journal of neurodevelopmental disorders, Dec. 2018, 10(1):1-10. cited by applicant
Magari et al., “Pharmacologic control of a humanized gene therapy system implanted into nude mice,” The Journal of clinical investigation, Dec. 1, 1997, 100(11):2865-2872. cited by applicant
Miura et al., “Distinct expression of Cb1n family mRNAs in developing and adult mouse brains,” European Journal of Neuroscience, Aug. 2006, 24(3):750-760. cited by applicant
Naur et al., “Ionotropic glutamate-like receptor δ2 binds D-serine and glycine,” Proceedings of the National Academy of Sciences, Aug. 28, 2007, 104(35):14116-14121. cited by applicant
Navratilova et al., “Selective modulation of tonic aversive qualities of neuropathic pain by morphine in the central nucleus of the amygdala requires endogenous opioid signaling in the anterior cingulate cortex,” Pain, Mar. 1, 2020, 161(3): 39 pages. cited by applicant
Neugebauer et al., “The amygdala and persistent pain,” The Neuroscientist, Jun. 2004, 10(3): 15 pages. cited by applicant
Neugebauer et al., “Synaptic plasticity in the amygdala in a model of arthritic pain: differential roles of metabotropic glutamate receptors 1 and 5,” Journal of neuroscience, Jan. 1, 2003, 23(1):52-63. cited by applicant
Neugebauer, “Amygdala Pain Mechanisms,” Handbook of Experimental Pharmacology, 2015, 227:261-284. cited by applicant
No et al., “Ecdysone-inducible gene expression in mammalian cells and transgenic mice,” Proceedings of the National Academy of Sciences, Apr. 16, 1996, 93(8):3346-3351. cited by applicant
Orkin et al., “Thalassemia due to a mutation in the cleavage-polyadenylation signal of the human beta-globin gene,” The EMBO journal, Feb. 1985, 4(2):453-456. cited by applicant
Otsuka et al., Roles of Cb1n1 in non-motor functions of mice. Journal of Neuroscience. Nov. 16, 2016;36(46):11801-16. cited by applicant
Piccioli et al., “Neuroantibodies: ectopic expression of a recombinant anti-substance P antibody in the central nervous system of transgenic mice,” Neuron, Aug. 1, 1995, 15(2):373-384. cited by applicant
Piccioli et al., “Neuroantibodies: molecular cloning of a monoclonal antibody against substance P for expression in the central nervous system,” Proceedings of the National Academy of Sciences, Jul. 1, 1991, 88(13):5611-5615. cited by applicant
Powell et al., “Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy,” Discovery medicine, Jan. 1, 2015, 19(102): 15 pages. cited by applicant
Schek et al., “Definition of the upstream efficiency element of the simian virus 40 late polyadenylation signal by using in vitro analyses,” Molecular and Cellular Biology, Dec. 1, 1992, 12(12):5386-5393. cited by applicant
Schwaber et al., “Neurons containing calcitonin gene-related peptide in the parabrachial nucleus project to the central nucleus of the amygdala,” Journal of Comparative Neurology, Apr. 15, 1988, 270(3):416-426. cited by applicant
Seigneur et al., “Cerebellins are differentially expressed in selective subsets of neurons throughout the brain,” Journal of Comparative Neurology, Oct. 15, 2017, 525(15):3286-3311. cited by applicant
Spike et al., “A quantitative and morphological study of projection neurons in lamina I of the rat lumbar spinal cord,” European Journal of Neuroscience, Nov. 2003, 18(9):2433-2448. cited by applicant
Staff et al., “Chemotherapy-induced peripheral neuropathy: a current review,” Annals of neurology, Jun. 2017, 81(6): 19 pages. cited by applicant
Stein et al., “The osteocalcin gene: a model for multiple parameters of skeletal-specific transcriptional control,” Molecular biology reports, Aug. 1997, 24(3):185-196. cited by applicant
Sugimura et al., “Synaptic and network consequences of monosynaptic nociceptive inputs of parabrachial nucleus origin in the central amygdala,” Journal of neurophysiology, Jun. 1, 2016, 115(6):2721-2739. cited by applicant
Szymanski et al., “Development and validation of a robust and versatile one-plasmid regulated gene expression system,” Molecular Therapy, Jul. 1, 2007, 15(7):1340-1347. cited by applicant
Tao et al., “Postsynaptic δ1 glutamate receptor assembles and maintains hippocampal synapses via Cb1n2 and neurexin,” Proceedings of the National Academy of Sciences, Jun. 5, 2018, 115(23):E5373-E5381. cited by applicant
Thompson et al., “Amygdala plasticity and pain,” Pain research & management, Dec. 10, 2017, 2017:8296501, 13 pages. cited by applicant
Thompson et al., “Small conductance calcium activated potassium (SK) channel dependent and independent effects of riluzole on neuropathic pain-related amygdala activity and behaviors in rats,” Neuropharmacology, Aug. 1, 2018, 138:219-231. cited by applicant
Uemura et al., “Trans-synaptic interaction of GluRδ2 and Neurexin through Cb1n1 mediates synapse formation in the cerebellum,” Cell, Jun. 11, 2010, 141(6):1068-1079. cited by applicant
Varrassi et al., “Towards an effective and safe treatment of inflammatory pain: a Delphi-guided expert consensus,” Advances in therapy, Oct. 2019, 36(10):2618-2637. cited by applicant
Wang et al., “Ligand-inducible and liver-specific target gene expression in transgenic mice,” Nature biotechnology, Mar. 1997, 15(3):239-243. cited by applicant
Wang et al., “Positive and negative regulation of gene expression in eukaryotic cells with an inducible transcriptional regulator,” Gene therapy, May 1997, 4(5):432-441. cited by applicant
Watabe et al., “Synaptic potentiation in the nociceptive amygdala following fear learning in mice,” Molecular brain, Dec. 2013, 6(1):1-14. cited by applicant
Wei et al., “The Cb1n family of proteins interact with multiple signaling pathways,” Journal of neurochemistry, Jun. 2012, 121(5):717-729. cited by applicant
Wilson et al., “Dual and opposing functions of the central amygdala in the modulation of pain, ” Cell reports, Oct. 8, 2019, 29(2): 21 pages. cited by applicant
Woychik et al., “Requirement for the 3′flanking region of the bovine growth hormone gene for accurate polyadenylylation,” Proceedings of the National Academy of Sciences, Jul. 1, 1984, 81(13):3944-3948. cited by applicant
Yadav et al., “Deletion of glutamate delta-1 receptor in mouse leads to enhanced working memory and deficit in fear conditioning,” PloS one, Apr. 3, 2013, 8(4):e60785, 12 pages. cited by applicant
Yadav et al., “Mutations in the transmembrane domain M3 generate spontaneously open orphan glutamate delta 1 receptor,” Brain research, Mar. 25, 2011, 1382:1-8. cited by applicant
Ye et al., “Cell-type specific parallel circuits in the bed nucleus of the stria terminalis and the central nucleus of the amygdala of the mouse,” Brain Structure and Function, Apr. 2019, 224(3):1067-1095. cited by applicant
Younger et al., “Pain outcomes: a brief review of instruments and techniques,” Current pain and headache reports, Feb. 1, 2009, 13(1):39-43. cited by applicant
Yuzaki et al., “A GluD coming-of-age story,” Trends in neurosciences, Mar. 1, 2017, 40(3): 13 pages. cited by applicant
Yuzaki, “Two classes of secreted synaptic organizers in the central nervous system,” Annual review of physiology, Feb. 10, 2018, 80:243-262. cited by applicant
Zhao et al., “Activity-dependent synaptic recruitment of neuroligin 1 in spinal dorsal horn contributed to inflammatory pain,” Neuroscience, Sep. 15, 2018, 388:1-10. cited by applicant

edspgr.12246058